Table 2.
Multivariable Analysis of Factors Related to Relapse among MassHealth Members with Opioid Use Disorders Who Started a Buprenorphine Treatment Episode in 2007 (N = 2,049)†
| Factor | Everyone Coefficient (95% CI) | Medium/High-dose Groups‡ Coefficient (95% CI) |
|---|---|---|
| Intercept | 0.193 (0.12, 0.26)*** | 0.202 (0.12, 0.29)*** |
| Age in 2007 (10 years units) | −0.014 (−0.03, <0.01)* | −0.024 (−0.04, −0.01)** |
| Gender | ||
| Female | Reference | Reference |
| Male | 0.050 (0.03, 0.07)*** | 0.047 (0.02, 0.08)** |
| Race | ||
| Nonwhite | Reference | Reference |
| White | 0.024 (<0.01, 0.05)* | 0.024 (−0.01, 0.05) |
| MassHealth plan | ||
| FFS | Reference | Reference |
| PCC plan | −0.004 (−0.05, 0.04) | −0.024 (−0.08, 0.03) |
| Disease burden (CDPS) | 0.020 (0.01, 0.03)*** | 0.024 (0.01, 0.03)*** |
| Episode length (in 10 day units) | −0.043 (−0.05, −0.04)*** | −0.030 (−0.04, −0.02)*** |
| Study month (1–24) | −0.005 (−0.01, <0.01)*** | −0.005 (−0.01, <0.01)** |
| Policy implementation | ||
| Prior to 7/1/08 | Reference | Reference |
| After 7/1/08 | 0.046 (0.01, 0.08)** | 0.045 (0.01, 0.08)* |
†
Generalized estimating equations (GEE) analysis.
‡
Includes members in the Medium- (>16 mg and ≤24 mg), and High- (>24 mg) dose groups, based on the member's highest buprenorphine dose in 2007.
*
Significant at p < .05;
**
Significant at p < .01;
***
Significant at p < .001.